Treatment of a genetic brain disease by CNS-wide microglia replacement
Yohei Shibuya(Stanford University), Marius Wernig(California Institute for Regenerative Medicine), Tony Wyss‐Coray(Neurosciences Institute), Paul Marcoux(Stanford University), Marius Marc-Daniel Mader(Stanford University), Manuel Mohr(Stanford University), Hiromitsu Nakauchi(Japan Science and Technology Agency), Ishan Kumar(Stanford University), Thomas C. Südhof(Howard Hughes Medical Institute), Kevin K. Kumar(Stanford University), L Angel Ayala(Stanford University), Mu Zhou(Stanford University), Benjamin Liou(Cincinnati Children's Hospital Medical Center), Ying Sun(University of Cincinnati Medical Center), F. Chris Bennett(Children's Hospital of Philadelphia), Frank L. Heppner(Charité - Universitätsmedizin Berlin), Yongjin Yoo(California Institute for Regenerative Medicine), Ryō Yamamoto(Stanford University), Xiaoke Chen(Second Affiliated Hospital of Zhejiang University), Gernot Neumayer(Stanford University)
Cited by 126
Related Papers
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
|Immunity|2017|3k
Microglia states and nomenclature: A field at its crossroads
|Neuron|2022|1.8k
Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19
|Nature Neuroscience|2020|1.5k